World Health Organization (WHO). Schizophrenia. WHO. 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed 10 Jan 2022.

Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol. 2005;19:56–65.

Article  PubMed  Google Scholar 

Chien IC, Hsu JH, Lin CH, Bih SH, Chou YJ, Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res. 2009;111:17–22.

Article  PubMed  Google Scholar 

Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117:75–82.

Article  PubMed  Google Scholar 

Grajales D, Ferreira V, Valverde Á M. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells. 2019;8.

Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19:96.

Article  PubMed  PubMed Central  Google Scholar 

Mazereel V, Detraux J, Vancampfort D, van Winkel R, De Hert M. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol. 2020;11: 573479.

Article  Google Scholar 

Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007;24:481–5.

Article  CAS  PubMed  Google Scholar 

Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, et al. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013;210:825–9.

Article  CAS  PubMed  Google Scholar 

Yang W, Zheng L, Zheng B, Zeng S, Li J, Liang B, et al. A meta-analysis of abnormal glucose metabolism in first-episode drug-naive schizophrenia. Psychiatr Danub. 2020;32:46–54.

Article  PubMed  Google Scholar 

Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res. 2008;98:302–6.

Article  PubMed  Google Scholar 

Fernandez-Egea E, Walker R, Ziauddeen H, Cardinal RN, Bullmore ET. Birth weight, family history of diabetes and diabetes onset in schizophrenia. BMJ Open Diabetes Res Care. 2020;8: e001036.

Article  PubMed  PubMed Central  Google Scholar 

Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1:495.

Article  CAS  PubMed  Google Scholar 

Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiat. 2017;74:261–9.

Article  Google Scholar 

Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123:234–43.

Article  CAS  PubMed  Google Scholar 

Ding H, Xie M, Wang J, Ouyang M, Huang Y, Yuan F, et al. Shared genetics of psychiatric disorders and type 2 diabetes:a large-scale genome-wide cross-trait analysis. J Psychiatr Res. 2023;159:185–95.

Article  PubMed  Google Scholar 

Guest PC. Insulin resistance in schizophrenia. Adv Exp Med Biol. 2019;1134:1–16.

Article  CAS  PubMed  Google Scholar 

Kapogiannis D, Dobrowolny H, Tran J, Mustapic M, Frodl T, Meyer-Lotz G, et al. Insulin-signaling abnormalities in drug-naïve first-episode schizophrenia: transduction protein analyses in extracellular vesicles of putative neuronal origin. Eur Psychiatry. 2019;62:124–9.

Article  PubMed  Google Scholar 

Li Z, Chen J, Yu H, He L, Xu Y, Zhang D, et al. Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet. 2017;49:1576–83.

Article  CAS  PubMed  Google Scholar 

Polimanti R, Gelernter J, Stein DJ. Genetically determined schizophrenia is not associated with impaired glucose homeostasis. Schizophr Res. 2018;195:286–9.

Article  PubMed  Google Scholar 

Perry BI, Burgess S, Jones HJ, Zammit S, Upthegrove R, Mason AM, et al. The potential shared role of inflammation in insulin resistance and schizophrenia: a bidirectional two-sample mendelian randomization study. PLoS Med. 2021;18: e1003455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Chen P, Chen J, Xu Y, Wang Q, Li X, et al. Glucose and insulin-related traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study. EBioMedicine. 2018;34:182–8.

Article  PubMed  PubMed Central  Google Scholar 

Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284–9.

Article  PubMed  Google Scholar 

Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004;47:S67-71.

Article  PubMed  Google Scholar 

Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry. 2003;48:345–7.

Article  PubMed  Google Scholar 

Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 23):30–8.

CAS  PubMed  Google Scholar 

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290–6.

Article  PubMed  Google Scholar 

Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Häring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96:1169–209.

Article  CAS  PubMed  Google Scholar 

Cetinkalp S, Simsir IY, Ertek S. Insulin resistance in brain and possible therapeutic approaches. Curr Vasc Pharmacol. 2014;12:553–64.

Article  CAS  PubMed  Google Scholar 

Chadha R, Meador-Woodruff J. S192. AKT-MTOR signaling pathway is downregulated in schizophrenia. Schizophr Bull. 2018;44:S400.

Article  PubMed Central  Google Scholar 

Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004;36:131–7.

Article  CAS  PubMed  Google Scholar 

Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res. 2006;84:1–14.

Article  PubMed  Google Scholar 

Wijtenburg SA, Kapogiannis D, Korenic SA, Mullins RJ, Tran J, Gaston FE, et al. Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia. Schizophr Res. 2019;208:324–30.

Article  PubMed  PubMed Central  Google Scholar 

Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.

Article  PubMed  PubMed Central  Google Scholar 

Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318:1925–6.

Article  PubMed  Google Scholar 

Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al. Mendelian randomization. Nat Rev Methods Primer. 2022;2:6.

Article  CAS  Google Scholar 

Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and interpretation of shared genetic influences on 42 human traits. Nat Genet. 2016;48:709–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ryskalin L, Limanaqi F, Frati A, Busceti CL, Fornai F. mTOR-Related brain dysfunctions in neuropsychiatric disorders. Int J Mol Sci. 2018;19:2226.

Article  PubMed  PubMed Central  Google Scholar 

Steiner J, Bernstein HG, Schiltz K, Müller UJ, Westphal S, Drexhage HA, et al. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:287–94.

Article  CAS  PubMed  Google Scholar 

Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK, et al. The possible role of the Akt signaling pathway in schizophrenia. Brain Res. 2012;1470:145–58.

Article  CAS  PubMed  Google Scholar 

de Bartolomeis A, De Simone G, De Prisco M, Barone A, Napoli R, Beguinot F, et al. Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment Mol Psychiatry. 2023;28:2811–25.

PubMed